



## **IRRAS AB – Q1 Report 2019 – invitation to conference call and webcast**

Today Tuesday May 7, at 04.00 p.m. CET IRRAS will host a conference call and an online presentation of its Q1 2019 interim report (which was published earlier today 08.00 a.m. CET).

The dial-in numbers for the conference call are:

Sweden: +46 8 5664 2707

Rest of the world: +44 33 3300 9034

The presentation will also be webcast and can be accessed from the following web address:

<https://financialhearings.com/event/11740>

Hosts: President CEO Kleanthis G. Xanthopoulos, Ph.D. and CFO and Deputy CEO Fredrik Alpsten

### **Investor and Media Contact:**

Fredrik Alpsten

CFO and Deputy CEO

+46 706 67 31 06

[fredrik.alpsten@irras.com](mailto:fredrik.alpsten@irras.com)

### **About IRRAS**

IRRAS AB (Nasdaq First North Premier: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery.

The company's initial product, *IRRAflow*, is the world's first "irrigating ventricular drain." Its unique mechanism of action addresses the complications associated with the current methods of managing intracranial fluid by using a dual lumen catheter that combines active irrigation with ongoing fluid drainage. Additionally, *IRRAflow* incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels. *IRRAflow* received FDA-clearance in July 2018.

With its unique product portfolio, protected by property patents and patent applications, IRRAS is well positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit [www.irras.com](http://www.irras.com).